Shanghai Synergy Pharmaceutical Sciences Co., Ltd., A wholly owned subsidiary of Huahai Pharmaceutical Co., Ltd.
Monday, June 03, 2024
Company Presentation
![Multiple Therapeutics](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/blank.png)
Company Presentation Theater 3
A clinical stage biotech company located at Zhangjiang Hi-Tech Park, Shanghai. The company is dedicated to innovative small molecule therapeutics research and development. Currently, the company has one drug candidate in Phase II study, two in Phase I study, and another one cleared for Phase I study. The areas of therapeutic focus are cardiovascular, anti-cancer, neuroscience, and autoimmune diseases.
![Shanghai Synergy Pharmaceutical Sciences Co., Ltd., A wholly owned subsidiary of Huahai Pharmaceutical Co., Ltd.](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1733344-1-JPG.png)
Company Website:
http://www.hhtpharm.com
Lead Product in Development:
HHT201, Donepezil Pamoate long lasting injectable for treating Alzheimer's disease.
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Company HQ City
Shanghai
Company HQ State
China
Company HQ Country
China
CEO/Top Company Official
Min Li, PhD, Board Chair
Development Phase of Primary Product
Phase I
Primary Speaker